Sun Pharma introduces STARIZO to tackle drug-resistant skin infections in India

Sun Pharmaceutical Industries Limited has introduced STARIZO (Tedizolid Phosphate) to the Indian market, a novel antibacterial treatment targeting Acute Bacterial Skin and Skin Structure Infections (ABSSSI), particularly those caused by drug-resistant bacteria such as methicillin-resistant Staphylococcus aureus (MRSA). This launch represents a significant advancement in addressing the growing concern of antibiotic-resistant infections in India.

Skin and soft tissue infections are prevalent in India, constituting around 29-32% of all infections reported during 2018-2019. The treatment of ABSSSI is often complicated by comorbid conditions such as diabetes, obesity, and renal or hepatic dysfunction, which are common among affected patients. The incidence of invasive Staphylococcus aureus infections, particularly those caused by MRSA, has been on the rise, with rates increasing from 28.4% in 2016 to 42.6% in 2021. This sharp increase underscores the urgent need for innovative treatment options.

STARIZO, an oxazolidinone-class antibacterial, offers a potent and convenient treatment option for patients suffering from ABSSSI. Its unique advantage lies in its once-a-day dosing over a six-day period, compared to the traditional twice-daily regimen required over 10-14 days with other antibiotics. This simplified regimen not only improves patient compliance but also reduces the duration of drug exposure, which is particularly beneficial for elderly patients and those with comorbid conditions​.

The drug’s broad spectrum of activity against gram-positive organisms, including MRSA, positions it as a critical tool in the fight against drug-resistant infections. Additionally, STARIZO does not require dose adjustments for elderly patients, those with hepatic or renal impairment, or patients undergoing haemodialysis, making it a versatile option across diverse patient populations​.

Sun Pharma’s partnership with MSD (Merck Sharp & Dohme) to develop, manufacture, and commercialize Tedizolid Phosphate in India reflects the company’s ongoing commitment to enhancing patient care through innovative solutions. As the largest pharmaceutical company in India and a leading player in global markets, Sun Pharma continues to push the boundaries of healthcare with cutting-edge treatments like STARIZO.